Group 1 - Dongguan Securities announced the return of Pan Haibiao as chairman, aiming to further promote the company's IPO process after a decade of planning [1] - Pan Haibiao joined Dongguan Securities in March 2004 and served as general manager from October 2020 until his departure in May 2024 [1] - The IPO journey began in June 2015 but was halted in 2017 due to issues related to the major shareholder, Jinlong Co., Ltd., and compliance problems [1] Group 2 - The shareholding structure of Dongguan Securities changed after the completion of a transaction, with Dongguan Investment Control Group holding 32.9%, Dongguan Development Holdings 27.1%, and Jinlong Co., Ltd. 20% [2] - The actual control of Dongguan Securities is now held by the Dongguan State-owned Assets Supervision and Administration Commission, which owns 75.4% of the shares, removing obstacles for the IPO [2] - As of September this year, Dongguan Securities completed its seventh application but has not yet received the first round of inquiries, indicating that the IPO process is in its final stages [2]

New IPOs - The largest biotech IPO in Hong Kong for 2025 is initiated by Insilico Medicine (03696), which boasts the fastest global progress in AI drug development [1] - Lin Qingxuan (02657) will conduct its IPO from December 18 to December 23, attracting cornerstone investors like Fidelity [1] - Woan Robotics (06600) is set to launch its IPO during the same period, with an expected listing date of December 30 [1] - Meilian Holdings (02671) and Wuyi Vision (06651) will also hold their IPOs from December 18 to December 23, both expected to list on December 30 [1] - Xun Ce (03317) will follow the same IPO schedule, with a listing anticipated on December 30 [1] - Zhihui Mining (02546) achieved a remarkable 5248.15 times subscription in its public offering, with a listing date of December 19 [1] - China National Airlines (00753) plans to invest in Shenzhen Airlines' equity financing, with Kunhang Investment, a state-owned entity, being shortlisted [1] - Sensetime-W (00020) intends to place 1.75 billion new Class B shares, aiming to raise approximately HKD 3.146 billion [1] - Fosun Pharma (02196) is enhancing its overseas innovative drug strategy by signing a cooperation and option agreement with Clavis Bio [1] - WuXi AppTec (02359) invested around EUR 30 million to acquire a 3.22% stake in a French biopharmaceutical fund [1] - Minhua Holdings (01999) plans to acquire 100% equity in the American soft furniture company Gainline Recline Intermediate Corp [1] Share Buybacks - Tencent Holdings (00700) repurchased 1.055 million shares for HKD 636 million on December 18 [2] - Xiaomi Group-W (01810) spent HKD 151 million to buy back 3.75 million shares on the same day [2] - COSCO Shipping Holdings (01919) repurchased 5.9 million shares for HKD 80.557 million [2] - Country Garden Services (06098) bought back 2.7 million shares for HKD 17.136 million [2] - Jiangsu Ninghu Expressway (00177) saw an increase of 52.862 million shares by Yunsong Capital [2]

Western Dig. Those are not the ones to be in. They can go on, but Mike is the one that is really outstanding.Sant who [music and bell] said this could happen two years ago in January. Two years ago, he said this could happen and it happened. Congratulations.>> That's good. Let's get the opening bell here in the CNBC realtime exchange of the big board. It's Depard Medical, maker of the Sincardia Total Artificial Heart, celebrating a recent IPO.And at the NASDAQ, it's IT and enterprise software company Metall ...

Core Viewpoint - Gude Electric Material is preparing for an IPO on the Shenzhen Stock Exchange's Growth Enterprise Market, aiming to raise 1.17571 billion yuan, with 300 million yuan allocated for working capital supplementation despite having sufficient cash reserves and no short-term debt [2][3][5]. Financial Health - The company has 271 million yuan in cash and no short-term loans, with a low debt-to-asset ratio and only 7.6842 million yuan in current liabilities, indicating minimal repayment pressure [3][5]. - Gude Electric Material has consistently paid dividends over the past three years, totaling approximately 74.76 million yuan, raising questions about the necessity of additional liquidity [3][5]. Revenue and Profitability Trends - Revenue and gross margin have shown an upward trend from 2022 to 2024, but growth has slowed significantly in 2025, with a revenue increase of only 15.72% in the first half of the year compared to over 70% in the previous two years [3][7]. - The gross margin for the main business decreased from 37.73% in 2024 to 33.92% in the first half of 2025, indicating potential challenges in maintaining profitability [3][7]. International Sales and Cost Structure - A significant portion of the company's revenue comes from international sales, which accounted for 44.29% in 2024, although this figure has shown signs of slowing in 2025 [3][7]. - Logistics costs and import duties have surged, rising from 12.01 million yuan in 2022 to 61.69 million yuan in 2024, representing 11.44% of the main business costs in 2025 [3][7]. Research and Development (R&D) Expenditure - Gude Electric Material's R&D expense ratio has consistently been below the industry average, remaining around 4%, while actual R&D spending has increased significantly, with a compound annual growth rate of 36.65% from 2022 to 2024 [4][12]. - The company has faced scrutiny regarding the rapid increase in R&D projects and expenditures, with questions raised about the necessity and authenticity of these investments [12][13]. Compliance and Governance Issues - The company has been subject to multiple administrative penalties related to safety, environmental protection, and information disclosure, highlighting potential weaknesses in internal management and compliance controls [4][16]. - A warning letter from the Jiangsu Securities Regulatory Bureau revealed a long-standing issue of concealed shareholding arrangements, raising concerns about governance and transparency [3][6].

【文/羽扇观金工作室】 近日，重庆金融监管局一纸罚单将重庆三峡银行推上风口浪尖。这家重庆市属重点城商行因内控管理不 到位、违规发放贷款、贷前贷中贷后"三查"严重不尽职、虚增普惠金融服务数据、金融资产风险分类不 准确导致拨备计提不足等八项核心违规行为，被处以890万元罚款。 更值得关注的是，计划财务部副总经理刘鸣昊因员工行为管理不到位被终身禁业，按照银行内控的基本 原则，财务部门应当对业务数据进行独立复核，对异常指标及时预警。但从虚增普惠金融服务数据这一 违规行为来看，财务条线非但没有发挥监督制衡作用，反而可能参与了数据造假的全过程。 监管此次追责范围延伸至已离任人员，传递出明确信号：合规责任不因职务变动而免除。丁世录虽已于 2022年落马，但其任期内的违规行为仍被追溯处罚。这一做法打破了过去人走账销的侥幸心理，对在任 高管形成强烈震慑。 引发行业关注的是，时任董事长丁世录、计划财务部副总经理刘鸣昊被终身禁止从事银行业工作，副行 长王良平、胥玲等6名中高层管理人员分别被取消任职资格5至10年或警告罚款。 这已是该行年内第二次领到百万级罚单——7月，其因反洗钱、账户管理等九项违规被央行重庆市分行 罚款559.2万 ...

Group 1 - The core viewpoint of the report indicates that the A-share market in mainland China is expected to see significant growth in new listings and financing amounts by 2025, with 114 companies projected to go public and a total financing amount of 129.6 billion RMB [1] - In 2024, 100 companies are expected to be listed, raising 66.8 billion RMB, indicating a 14% increase in the number of new stocks and a 94% increase in financing amounts in 2025 compared to 2024 [1] - The Shanghai Stock Exchange is anticipated to lead with a new stock financing amount of 80 billion RMB in 2025, while the Shenzhen Stock Exchange will have the highest number of new listings at 48 companies [1] Group 2 - The report highlights that the performance of the A-share market in 2025 will continue the momentum from 2024, driven by supportive policies and new listings from energy, resources, and technology companies [1] - The Hong Kong IPO market is expected to rebound strongly in 2025, with 114 new listings and approximately 286.3 billion HKD in financing, marking a 63% increase in new stock numbers and more than doubling the financing amount compared to 2024 [2] - The report predicts that the Hong Kong market will regain its position as the global leader in new stock listings, benefiting from various reforms such as simplified listing approval processes and new pricing mechanisms for IPOs [2] Group 3 - Approximately 63 Chinese companies are expected to list in the United States in 2025, raising around 1.12 billion USD, which represents a 7% increase in the number of new stocks but a 41% decrease in financing amounts compared to 2024 [3] - The largest two new listings from Chinese companies in the U.S. are anticipated to come from a consumer company and a pharmaceutical company [3]

RT Giacomo Tognini (@giacomotognini)Medical supplies giant Medline went public today in this year's biggest IPO. @DurotMatthew and I dug into public filings for @Forbes and found that 5 members of the Mills family-who founded Medline in 1966 and sold a majority in 2021-are now billionaires.https://t.co/2JiRnVAdct ...

Joining us now to discuss the year of IPOs and his outlook for 2026 is NASDAQ President Nelson Griggs. Good morning to you. Congratulations on what was a pretty great 2025.>> Yeah. >> When you think about 2026, people are already speculating about names like Open AI and Anthropic and SpaceX. I mean, we could be in a whole new realm.So, where are we really. And is that uh pie in the sky or is that reality. >> Uh, I think there's a lot of reality there.I think this year we went in probably with higher expecta ...

Joining us now to discuss the year of IPOs and his outlook for 2026 is NASDAQ President Nelson Griggs. Good morning to you. Congratulations on what was a pretty great 2025.>> Yeah. >> When you think about 2026, people are already speculating about names like Open AI and Anthropic and SpaceX. I mean, we could be in a whole new realm.So, where are we really. And is that uh pie in the sky or is that reality. >> Uh, I think there's a lot of reality there.I think this year we went in probably with higher expecta ...

成立近八年时间，江苏展芯半导体技术股份有限公司（以下简称"江苏展芯"）正式向A股市场发起冲击。深交所官网显示，公司创业板IPO于12月17日获得 受理。本次冲击IPO背后，公司2024年净利出现明显下滑，不过2025年上半年净利已有所回升。此外，梳理江苏展芯招股书，公司与A股公司宏达电子关系 紧密，宏达电子被认定为江苏展芯关联方。针对公司相关问题，江苏展芯方面于12月18日接受了北京商报记者的采访。 | 公司全称 | 江苏展芯半导体技术股份有限公司 | 公司简称 | | --- | --- | --- | | 受理日期 | 2025-12-17 | 更新日期 | | 审核状态 | 已受理 | 预计融资金额(亿元 | 公司回应净利变动 江苏展芯成立于2018年3月，是一家专注于高可靠模拟芯片及微模块产品的研发设计、测试及销售的国家级专精特新"小巨人"企业，主要服务于军工电子产 业链，配套供应高可靠集成电路及微模块产品。 本次冲击IPO背后，江苏展芯净利呈现明显波动。 本次冲击上市，江苏展芯拟募集资金约8.9亿元，扣除发行费用后，将投入高可靠性电源管理芯片及信号链芯片研发及产业化项目、总部基地及研发中心建 设项目 ...